The global economy is in its steepest slowdown since 1970. The IMF has forecast that global economic growth will slow to 3.2% in 2022 and 2.9% in 2023 from 6.1% in 2021. While high inflation continues to make headlines across the globe, spiralling healthcare costs need to be addressed. Biosimilars, which provide affordable access to … Continue reading Biocon Biologics Approaching Closure of Transaction to Buy Out Viatris’ Biosimilars Business
Expect Biocon Biologics to become a fully integrated global biosimilars firm post Viatris buy: Kiran Mazumdar-Shaw
Biocon's Chairperson Kiran Mazumdar-Shaw in a QnA with FE’s Srinath Srinivasan, talks about the bold moves Biocon Biologics is making since 2021, including the recent acquisition of Viatris’ global biosimilars business, which will provide it a direct entry into the US & Europe with the acquired commercial engine in developed and key emerging markets. This … Continue reading Expect Biocon Biologics to become a fully integrated global biosimilars firm post Viatris buy: Kiran Mazumdar-Shaw
A Blog by Biocon 